The determination of citalopram, amitriptyline, clomipramine and their desmethyl metabolites after alkaline diethyl either extraction from plasma is achieved by high-performance liquid chromatography using two internal standards and mu Bondapak C18 as stationary phase. Elution is carried out isocratically at 0.5 or 1 ml/min with a mixture of acetonitrile-potassium dihydrogen phosphate-distilled water (45:50:5). Detection is monitored by absorption at 254 nm. The detection limit is less than 5 ng/ml for each compound. The coefficients of variation are between 1.3% and 9.4% for 8-360 ng/ml. Interference from 22 possible co-medications is discussed. The technique can be used for therapeutic monitoring of these antidepressants as well as in analytical toxicology.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0378-4347(85)80081-5DOI Listing

Publication Analysis

Top Keywords

determination citalopram
8
citalopram amitriptyline
8
amitriptyline clomipramine
8
high-performance liquid
8
liquid chromatography
8
clomipramine plasma
4
plasma reversed-phase
4
reversed-phase high-performance
4
chromatography determination
4
clomipramine desmethyl
4

Similar Publications

Insights into prescribing patterns for antidepressants: an evidence-based analysis.

BMC Med Inform Decis Mak

January 2025

Department of Health Administration and Policy, College of Public Health, George Mason University, 4400 University Dr, Fairfax, VA, 22030, USA.

Background: Antidepressants are a primary treatment for depression, yet prescribing them poses significant challenges due to the absence of clear guidelines for selecting the most suitable option for individual patients. This study aimed to analyze prescribing patterns for antidepressants across healthcare providers, including physicians, physician assistants, nurse practitioners, and pharmacists, to better understand the complex factors influencing these patterns in the management of depression.

Methods: Least Absolute Shrinkage and Selection Operator (LASSO) regression was employed to identify variables that explained the variation in the prescribed antidepressants, utilizing a large number of claims.

View Article and Find Full Text PDF

Background: In the past few decades, selective serotonin reuptake inhibitors (SSRIs) became widely used antidepressants worldwide. Therefore, the adverse reactions of patients after SSRI administration became a public and clinical concern. In this study, we conducted a pharmacovigilance study using the Adverse Event Reporting System (FAERS) database of the US Food and Drug Administration.

View Article and Find Full Text PDF

Cocaine use disorder (CUD) is associated with executive functioning impairments linked to serotonergic function. Previous studies reported efficacy with the selective serotonin reuptake inhibitor citalopram in reducing cocaine use. The current study explored moderation and mediation of citalopram effects on cocaine use by performance across executive function domains.

View Article and Find Full Text PDF

Effect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.

BMC Pharmacol Toxicol

January 2025

Department of Community Medicine, Islamic International Medical College (IIMC), Riphah International University, Rawalpindi, Pakistan.

Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.

Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks.

View Article and Find Full Text PDF

Objective: Patients with major depressive disorder (MDD) often face poor health outcomes. Additionally, patients with multiple hospitalizations tend to have worse predicted disease prognosis. Antidepressant medications remain a first-line treatment option for MDD, but data evaluating the effects of different antidepressants on psychiatric readmission rates is lacking.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!